XML 94 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Stockholders' Equity (USD $)
In Millions
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Other Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Beginning Balance at Mar. 31, 2010 $ 7,532 $ 4 $ 4,756 $ (12) $ 7,236 $ 6 $ (4,458)
Beginning Balance, Shares at Mar. 31, 2010   359          
Beginning Balance, Treasury Stock, Shares at Mar. 31, 2010             (88)
Issuance of shares under employee plans 353   370        
Adjustments Related to Tax Withholding for Share-based Compensation             (17)
Issuance of shares under employee plans, shares   10          
Share-based compensation 137   137        
Tax benefit related to issuance of shares under employee plans 113   113        
Other Comprehensive Income (Loss), net of tax 81         81  
Net income 1,202       1,202    
Repurchase of common stock (2,032)   (37)       (1,995)
Repurchase of common stock, Shares (29.0)           (29.0)
Cash dividends declared: $0.80 for 2013, $0.80 for 2012 and $0.72 for 2011 per common share (188)       (188)    
Other 22     22      
Ending Balance at Mar. 31, 2011 7,220 4 5,339 10 8,250 87 (6,470)
Ending Balance, Shares at Mar. 31, 2011   369          
Ending Balance, Treasury Stock, Shares at Mar. 31, 2011             (117)
Issuance of shares under employee plans 143   167        
Shares Paid for Tax Withholding for Share Based Compensation             (1)
Adjustments Related to Tax Withholding for Share-based Compensation             (24)
Issuance of shares under employee plans, shares   4          
Share-based compensation 154   154        
Tax benefit related to issuance of shares under employee plans 46   46        
Other Comprehensive Income (Loss), net of tax (82)         (82)  
Net income 1,403       1,403    
Repurchase of common stock (1,850)   (140)       (1,710)
Repurchase of common stock, Shares (20.0)           (20.0)
Cash dividends declared: $0.80 for 2013, $0.80 for 2012 and $0.72 for 2011 per common share (202)       (202)    
Other (1)   5 (6)      
Ending Balance at Mar. 31, 2012 6,831 4 5,571 4 9,451 5 (8,204)
Ending Balance, Shares at Mar. 31, 2012   373          
Ending Balance, Treasury Stock, Shares at Mar. 31, 2012 (138)           (138)
Issuance of shares under employee plans 111   166        
Adjustments Related to Tax Withholding for Share-based Compensation             (55)
Issuance of shares under employee plans, shares   5          
Share-based compensation 167   167        
Tax benefit related to issuance of shares under employee plans 34   34        
Other Comprehensive Income (Loss), net of tax (70)         (70)  
Net income 1,338       1,338    
Repurchase of common stock (1,159)   162       (1,321)
Repurchase of common stock, Shares (13.0)           (13.0)
Retirement of treasury stock 0   (22)   (195)   217
Retirement of treasury stock, Shares   (2)          
Retirement of treasury stock, Shares             2.0
Cash dividends declared: $0.80 for 2013, $0.80 for 2012 and $0.72 for 2011 per common share (192)       (192)    
Other 10     10      
Ending Balance at Mar. 31, 2013 7,070 4 6,078 14 10,402 (65) (9,363)
Ending Balance, Shares at Mar. 31, 2013   376          
Ending Balance, Treasury Stock, Shares at Mar. 31, 2013 (149)           (149)
Beginning Balance at Dec. 31, 2012              
Net income [1],[2],[3] 259            
Retirement of treasury stock (217)       (195)    
Retirement of treasury stock, Shares 1.8            
Ending Balance at Mar. 31, 2013 $ 7,070       $ 10,402    
Ending Balance, Treasury Stock, Shares at Mar. 31, 2013 (149)            
[1] Financial results for the first, second and fourth quarters of 2013 include AWP litigation charges of $16 million pre-tax ($10 million after-tax), $44 million pre-tax ($27 million after-tax) and $12 million pre-tax ($8 million after-tax), which were recorded in operating expenses.
[2] Financial results for the second, third and fourth quarters of 2013 include the pre-tax receipts of $19 million, $8 million and $17 million representing our share of settlements of antitrust class action lawsuits brought against drug manufacturers, which were recorded as a reduction to cost of sales.
[3] Financial results for the fourth quarter of 2013 include the following pre-tax impairment charges: an equity investment of $191 million, goodwill of $36 million, and capitalized software held for sale of $10 million.